Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy of the supplement PEAPROSTIL 600
(FARMITALIA®) composed of Serenoa Repens combined with PEA in single or combined therapy with
alpha-blocker in the reduction of voiding symptoms in benign prostatic hyperplasia (BPH)
patients at low risk of progression to obstructing conditioning that need for surgical
therapy. Any adverse events, intolerance, allergic reactions, complications related to the
products used will be recorded throughout the study period.
Phase:
N/A
Details
Lead Sponsor:
Azienda Ospedaliero Universitaria Maggiore della Carita